A month into the program, early enrollees are already reporting denials and confusing eligibility rules
Since July 1, eligible Medicare beneficiaries have been able to access some of the most talked-about weight-loss drugs in the country for a flat $50 a month, down from list prices that can top $1,300. The program is called the Medicare GLP-1 Bridge, and it’s now a full month into its run. It’s a genuinely significant shift for older Americans living with obesity, but it’s also a temporary, narrowly scoped demonstration with real friction already showing up. Here’s what it actually covers, who qualifies, and what’s tripping people up so far.
What the Bridge Program Actually Covers
The Medicare GLP-1 Bridge is a short-term demonstration run by the Centers for Medicare & Medicaid Services (CMS), running from July 1, 2026 through December 31, 2027. Eligible beneficiaries enrolled in Medicare Part D drug plans pay a flat $50 monthly copay for a covered supply of Wegovy (semaglutide, injection or tablet), Zepbound (tirzepatide, KwikPen only), or Foundayo (tablet). That $50 figure doesn’t count toward your plan’s deductible or annual out-of-pocket limit, and it stays fixed regardless of your income or which stage of Part D coverage you’re in. Notably, the single-dose Zepbound pen and Zepbound vials are not covered under the program, only the KwikPen version.
The gap between the Bridge copay and full retail pricing is enormous. Wegovy’s list price runs around $1,350 a month, while Zepbound’s list price is roughly $1,080 to $1,270 depending on the source. Compared to that, a $50 flat copay is a dramatic reduction, which is exactly why the program has drawn so much attention since its announcement in May.
One Important Catch: Ozempic Isn’t Included
A detail that trips up a lot of people: Ozempic and Wegovy share the exact same active ingredient, semaglutide, made by the same manufacturer, Novo Nordisk. But Ozempic is approved for Type 2 diabetes management, not weight loss, and the Bridge program only covers drugs with an FDA-approved weight-loss indication. If your doctor prescribes Ozempic off-label for weight loss, it isn’t covered under the Bridge, regardless of eligibility otherwise. Wegovy, by contrast, is FDA-approved both for chronic weight management and for reducing cardiovascular risk in adults with established heart disease who are overweight or obese, which is why it made the covered list.
Why This Program Exists, and Why It’s Temporary
CMS originally designed the Bridge as a six-month transition toward a longer-term program called BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), which was set to launch in January 2027 and shift responsibility for covering these drugs onto private insurers running Part D plans. That plan hit a wall: insurers including CVS and UnitedHealthcare declined to participate voluntarily, citing concerns about the program’s structure and costs. In response, CMS extended the Bridge through the end of 2027 and says it plans to use data from the demonstration to build a case for broader insurer participation in BALANCE down the line. A CMS official told reporters the agency will “carefully track participation and outcomes” to inform smarter policy going forward.
Where Enrollees Are Already Running Into Trouble
A month in, real-world friction is already surfacing. On patient forums, enrollees have described prior-authorization denials despite appearing to meet the program’s stated criteria, confusion over how comorbidities like prediabetes or sleep apnea factor into eligibility, and cases where prescriptions were submitted to a regular Part D plan instead of being processed correctly under the Bridge. One recurring complaint: the eligibility page lists a BMI of 30+ with prediabetes as qualifying, but some prescribers report that prediabetes isn’t listed as an eligible comorbidity in their own guidance documents, a mismatch that has led to unexpected denials for people who believed they qualified.
Reader Takeaways and What Experts Are Saying
⚠️ Things to Keep in Mind
- This is a demonstration, not a permanent benefit: The Bridge program is scheduled to run only through December 31, 2027. Whether coverage continues afterward depends on how BALANCE negotiations with private insurers play out, so it’s not something to build long-term financial plans around just yet.
- Weight regain after stopping is a well-documented risk: One 2022 study found that people who stopped taking Wegovy regained roughly two-thirds of their prior weight loss within a year. Since the Bridge program’s future beyond 2027 is uncertain, it’s worth discussing an exit or maintenance plan with your doctor now, rather than after coverage potentially changes.
- Cost-assistance programs can’t be combined with the $50 copay: Programs like Extra Help cannot be layered on top of the Bridge copay, and the $50 amount doesn’t change based on income or which Part D coverage stage you’re in. Double-check with your plan before assuming additional savings apply.
- Confirm your prescription is being routed correctly: Some enrollees have had prescriptions mistakenly submitted through their regular Part D benefit rather than the Bridge program. If your claim is denied, it’s worth confirming with your pharmacy and plan that it was processed under the correct program before assuming you’re ineligible.
📌 What Officials and Experts Are Saying
- Jamey Millar, EVP of US Operations, Novo Nordisk: Called obesity “a serious, common chronic disease facing older Americans,” and noted that Wegovy’s cardiovascular risk-reduction benefit is particularly relevant for seniors who carry a high burden of both obesity and heart disease.
- CMS officials: Say the agency plans to track participation and health outcomes closely during the Bridge period specifically to build the evidence base needed to bring reluctant private insurers into the longer-term BALANCE model.
- Dr. Peminda Cabandugama, endocrinologist, Cleveland Clinic: Has noted more broadly that GLP-1 drug costs have “come down significantly” over the past year across various access channels, though list prices for standard retail fills remain well above $1,000 a month absent a savings program like the Bridge.
Taken together, the Medicare GLP-1 Bridge is a real and meaningful cost reduction for the Medicare beneficiaries who qualify, but it’s a pilot program with a hard end date, uneven early execution, and an uncertain path to becoming permanent. If you’re on Medicare and considering the program, the practical next step is a direct conversation with your prescriber and Part D plan to confirm your specific eligibility, rather than assuming the general criteria will apply cleanly to your situation.
Sources
- Centers for Medicare & Medicaid Services — “Medicare GLP-1 Bridge” (cms.gov)
- CMS Newsroom — “Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries” (cms.gov)
- Medicare Rights Center — “GLP-1 Weight-Loss Drug Demonstration Begins July 2026” (medicarerights.org)
- CNBC — “Medicare obesity drug GLP-1 coverage starting July 1” (cnbc.com)
- PR Newswire — “Wegovy Access Expanded for Medicare Beneficiaries Living with Obesity Through the Medicare GLP-1 Bridge” (prnewswire.com)
- GoodRx — “Zepbound vs. Wegovy: Differences Between Weight-Loss Medications” (goodrx.com)